TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mean Binocular Defocus Visual Acuity (VA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Willingness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: difference in refraction results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse event and severe adverse event profile
Endpoint domain: Adverse events/effects
Primary endpoint: Everolimus trough level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with greater than 50% reduction in wound surface area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Fruit/Vegetable Intake (Cups)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Moderate to Vigorous Intensity Physical Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinician-Administered PTSD Scale (CAPS-5)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Patients With Confirmed Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Crestal cone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Neurological Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: composite endpoint of thromboembolism, all bleeding, all paravalvular leak and endocarditis, structural valve deterioration and late all cause death
Endpoint domain: Mortality/survival
Primary endpoint: Changes in mean aortic valve gradients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Aortic regurgitation grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Costs of the procedure
Endpoint domain: Resource use
Primary endpoint: Light touch test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 2-point discrimination test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of non ovulated follicles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Postprandial phosphoproteomic changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ordinal Scale of COVID19 Disease Severity at 14 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum bone turnover marker concentrations (P1NP and CTX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum bone factor concentrations (OPG and sclerostin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of repigmented surface area of the target lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % change in forearm vascular conductance (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Response rate after 2 cycles of forodesine therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular inflammatory mediators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Variation of blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Variation of heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Variation of pulse oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in serum IgG antibodies after first vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in serum IgG antibodies after second vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Non-serious and Serious Adverse Events During Trial
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Non-serious and Serious Adverse Events During Inhalation Procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Degree of anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Motor persistence score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Number of Packed Red Cells Units Transfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Patients With Late CMV Disease
Endpoint domain: Mortality/survival
Primary endpoint: Radiological assessment of bone resorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete resection of GIST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Newly Diagnosed Adolescent Girls and Young Women Living With HIV
Endpoint domain: Mortality/survival
Primary endpoint: Changes in adiposity level (BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in Malodor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skindex-16 Change Scores Between Baseline to Month 9 - Composite Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Skindex-16 Change Scores Between Baseline and Month 9 - Symptoms Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Skindex-16 Change Scores Between Baseline and Month 9 - Functioning Scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Self-efficacy for Lifestyle Physical Activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Medication Adherence Change from Baseline to 6 Months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Medication Adherence Change from 6 Months to 12 Months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Medication Adherence Change from Baseline to 12 Months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Shannon indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Simpson indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative abundance of Proteobacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative abundance of Firmicutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clostridium sensus_stricto_1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Escherichia - Shigella
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of treatment related Grade III/IV adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: NIR fluorescent signal in vivo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen therapy dependency time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Oxygen Uptake (Peak VO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Six (6) Minute Walk (6MW) Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minnesota Living With Heart Failure (MLWHF) Quality of Life Overall Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Subjects With Minimum 2-grade Improvement in HDSS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Absolute Change in Gravimetrically Measured Sweat Production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Word Recognition in Noise Abilities
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Word Recognition in Quiet Abilities
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mathematic Academic Performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Academic Language Performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: incidence of liver recurrence
Endpoint domain: Mortality/survival
Primary endpoint: incidence of postoperative biliary fistula
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Incisional SSI
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Adherent Participants With Incisional SSI
Endpoint domain: Adverse events/effects
Primary endpoint: Highest Vasoactive-Inotropic Score (VIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in pain response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Mobility Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Volume of mandible irradiated to >55 Gy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily phenylalanine control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Target Lesion Primary Patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from localised or systemic serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: end-systolic LV volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: left ventricular ejection fraction (LV-EF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Cortical Gama-aminobutyric Acid Levels (GABA Levels)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC) of GP2013
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed concentration of GP2013
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach maximum concentration of GP2013
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Quality PET and PET/MR Images With Regional Myocardial Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Human Serum Bactericidal Activity (hSBA) Geometric Mean Titers (GMTs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ELISA Geometric Mean Concentration (GMCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Dental implant stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maxillary sinus augmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Occurrence of Treatment-emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Excess Central Macular Thickening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Hemoglobin A1c (HbA1c) %
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: tmax (time to reach maximum concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of telmisartan treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cough grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Failure of restorations
Endpoint domain: Adverse events/effects
Primary endpoint: Oral feeding readiness in preterm infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral feeding skills in preterm infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: long term neurocognitive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of Participants With Virologic Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Motor Activity Log (MAL) Arm Use Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of CETP activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUCτ,ss of BI 10773
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax,ss of BI 10773
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-∞ of glimepiride
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of glimepiride
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of Output Under the Base Plate (Leakage)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immediate reduction in pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PGC-1alpha RNA Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PGC-1alpha Protein Abundance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All-cause discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: change from baseline in lean tissue mass at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Upper body strength at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Lower body strength at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed Up and Go Cognitive (TUGcog)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed Up and Go manual (TUG manual)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreasing negative affectivity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: increasing satisfaction with resource utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of postoperative wound infections
Endpoint domain: Adverse events/effects
Primary endpoint: Change in alanine aminotransferase (ALT) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Detection of psoriatic arthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of patients with G3-4 hyperglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of permanent discontinuation of alpelisib due to related AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After the First Injection
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the First Injection
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Serious Adverse Events (SAEs) After the First Injection
Endpoint domain: Adverse events/effects
Primary endpoint: psychological assessment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Peak Participant Subjective Ratings of Drug Liking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in leisure time spent being non-sedentary
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Severity of postoperative pain in the perioperative period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity and incidence of chronic post-thoracotomy pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health-related quality of life (HRQL) measured by the SF-36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Psychological resiliency measured by Connor Davidson Resiliency Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants That Experienced Clinical Worsening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive Assessment: Trail Making Test Part B
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive Assessment: Hopkins Verbal Learning- Immediate Recall
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive Assessment: Forward Digit Span Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Sustained Viral Response (SVR) at IL28B Genotype rs12979860
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Sustained Viral Response (SVR) at IL28B Genotype rs8099917
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Vein obliteration or abolition of reflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of Participants With Successful Implementation of BPE
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants Completing Six Month Treatment Period
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Technique success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial carbon dioxide pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean Number of Micturition Episodes Per 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants Reporting Satisfaction With Current Overactive Bladder (OAB) Treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: AUC of dabigatran in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl-Meyer Assessment Lower Extremity (FMA-LE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diabetes complications incidence
Endpoint domain: Mortality/survival
Primary endpoint: Mortality in Korean type 2 diabetic patients
Endpoint domain: Mortality/survival
Primary endpoint: variation of absolute counting of T cell subsets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: variation of serum IL-10, TGF-β1, IFN-γ concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Stent thromboses
Endpoint domain: Adverse events/effects
Primary endpoint: Gut microbial community differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CBF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of Patients Meeting the Criterion for Loss of Therapeutic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histologic validation of preoperative imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of agreement between diagnostic criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vd of hydrophilic antimicrobial agents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of infectious pathogens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of infectious pathogens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Spielberger State-Trait Anxiety Inventory scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Brain Phosphocreatine (PCr) Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of Abatacept
Endpoint domain: Adverse events/effects
Primary endpoint: First Cardiovascular Hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence and severity of other toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Caregiver Treatment Adherence at 1 Month and 4 Months Post-intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Ear assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: toxicity of pyrazoloacridine
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of coagulation abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean power output during intermittent exercise test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UCLA Loneliness Scale-8 (ULS-8)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: EORTC score for erythema, telangiectasia, edema, pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Fat-fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent HIV pseudovirus entry into cervical CD4+ T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total number of cervical CD4+ T cells infected ex vivo with HIV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Modified Roland-Morris Disability Questionnaire (RMDQ) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: width of lateral ventricles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of stroke or systemic embolic events (including TIA)
Endpoint domain: Mortality/survival